|Type||Public (LSE: SLN)|
Silence Therapeutics (AIM:SLN) is a biotechnology company that develops gene therapeutic technology based on RNA interference (RNAi). They are involved in developmental research of targeted RNAi therapeutics for the treatment of serious diseases. Formed in 1994 as a publicly traded drug research and development company, Silence Therapeutics has offices in London and Berlin, with its corporate headquarters based at 1 Lyric Square, London.
The targeting, delivery and on-going structural modification of sequences are the three platforms for Silence Therapeutics’s RNAi therapeutic development. These three platforms are:
- proprietary delivery using nanoparticles and lipoplex technology
- proprietary siRNA sequences complied using bioinformatics algorithms and scientific research
- development of siRNA structural features
Silence Therapeutics develops these structural modifications using three exclusive licences from the University of Massachusetts Amherst.
In 2005, the company acquired Atugen AG based in Germany, changing the company name to Silence Therapeutics AG. More recently in January 2010, Silence Therapeutics merged with Intradigm Corporation, a privately held biotechnology company in the United States that developed systematic RNA interference.
- "Google Finance Stock Exchange listing for Silence Therapeutics". Retrieved 2011-09-16.
- "Stockopedia - Silence Therapeutics Company History". Stockopedia. Retrieved 2011-09-16.
- "Silence Therapeutics Collaborative Partnerships". Silence Therapeutics. Retrieved 2011-09-26.